> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Advisory Panel to Review Wyeth’s Mylotarg Use
- URL: https://www.fdaweb.com/advisory-panel-to-review-wyeths-mylotarg-use/
- Published: 2017-06-08T12:00:00.000Z
- Updated: 2026-09-14T22:28:13.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138891

*Federal Register* notice: FDA has announced a 7/11 Oncologic Drugs Advisory Committee meeting. Panel members will review a Wyeth BLA for Mylotarg (gemtuzumab ozogamicin) for intravenous use, indicated for use in combination with daunorubicin and cytarabine for treating adult patients with previously untreated, *de novo* acute myeloid leukemia. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-06-07/pdf/2017-11817.pdf?ref=fdaweb.com).